2 weeks Ago By Defense World Staff
Innate Pharma S.A. ( NASDAQ:IPHA – Get Free Report ) saw a significant drop in short interest in September.
As of September 15th, there was short interest totalling 59,700 shares, a drop of 8.3% from the August 31st total of 65,100 shares. Based on an average daily trading volume, of 6,600 shares, the short-interest ratio is currently 9.
0 days. Analyst Ratings Changes Several research analysts recently issued reports on IPHA shares. Evercore ISI upgraded shares of Innate Pharma to a “strong-buy” rating in a research report on Monday, September 16th.
HC Wainwright reiterated a “buy” rating and set a $11.50 target price on shares of Innate Pharma in a research report on Friday, September 13th. View Our Latest Analysis on Innate Pharma Innate Pharma Stock Performance About Innate Pharma ( Get Free Report ) Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally.
The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Featured Stories Five stocks we like better than Innate Pharma Comparing and Trading High PE Ratio Stocks TJX Stock: A Buying Opportunity Before the Holiday Rush How Can Investors Benefit From After-Hours Trading Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge There Are Different Types of Stock To Invest In Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter .
.
